Drug
Ak105
Ak105: highest development phase Phase 3, developed by Akeso. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK105 NCT03866980 | Phase 3 | Lung Cancer Non-small Cell Stage IV |
| AK105 NCT04172571 | Phase 2 | Hepatocellular Carcinoma |
| AK105 NCT03866967 | Phase 2 | Nasopharyngeal Carcinoma |
Latest
No recent events.
Follow Ak105 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.